Streetbeat News

Revenues

BKE

Buckle reported a decrease in April comparable store net sales by 6.0% and an 8.1% decrease in net sales for the 4-week fiscal month ended May 4, 2024. The 13-week first quarter also saw a 9.0% decrease in comparable store net sales and a 7.2% decrease in net sales.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:29 am

APYX

Apyx Medical projects its FY24 revenues to be between $49.7M and $52.9M, which is around the $49.94M estimate but represents a decrease of about 5% compared to the previous year's growth of approximately 1%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:27 am

INSM

Insmed has reiterated its 2024 global revenue guidance for ARIKAYCE, projecting sales between $340 million and $360 million. This forecast suggests a 15% year-over-year growth compared to 2023.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:24 am

IQ

iQIYI reported a 12% sequential increase in total viewing time during the May Day holiday period compared to the previous period, indicating strong viewer engagement across multiple genres such as drama series, films, variety shows, and sports programming.

Portfolio Pulse from Charles Gross

May 09, 2024 | 11:22 am

BRAG

Bragg Gaming has reaffirmed its financial guidance for the full year 2024, projecting revenues between €102M-€109M ($109.7M-$117.2M) and Adjusted EBITDA between €15.2M-€18.5M ($16.3M-$19.9M), aligning with consensus estimates.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:22 am

FOUR

Shift4 Payments projects Q2 end-to-end payment volume to be between $39.0B-$41.0B and has reiterated its gross revenue less network fees forecast to be in the range of $312M-$317M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:21 am

RPRX

SNY

Royalty Pharma (RPRX) is set to acquire royalties and milestones on frexalimab from ImmuNext for approximately $525 million in cash, including estimated transaction costs. This deal grants Royalty Pharma 100% of net royalties on worldwide net sales of frexalimab up to $2.0 billion, with a share of royalties above this threshold going to ImmuNext shareholders. The acquisition also includes potential milestone payments from Sanofi (SNY), with frexalimab's royalties projected through 2041. Frexalimab, developed by Sanofi, is a pioneering anti-CD40 ligand monoclonal antibody.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:20 am

ADV

Advantage Solutions has reaffirmed its fiscal year 2024 guidance, expecting revenue and adjusted EBITDA growth in the low single digits. This forecast excludes the impact of divestitures completed within the fiscal year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:20 am

PGY

Pagaya Technologies has provided a revenue outlook for Q2, estimating revenues to be between $235 million and $245 million, closely aligning with the analyst estimate of $236.96 million.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:19 am

PGY

Pagaya Technologies has reaffirmed its revenue forecast for FY2024, projecting revenues to be in the range of $925 million to $1.05 billion, compared to the estimated $976.24 million by analysts.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 11:18 am